131 related articles for article (PubMed ID: 28975118)
1. Unraveling the spectrum of
Pai T; Bal M; Shetty O; Gurav M; Ostwal V; Ramaswamy A; Ramadwar M; Desai S
South Asian J Cancer; 2017; 6(3):113-117. PubMed ID: 28975118
[TBL] [Abstract][Full Text] [Related]
2. Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis.
Andersson J; Bümming P; Meis-Kindblom JM; Sihto H; Nupponen N; Joensuu H; Odén A; Gustavsson B; Kindblom LG; Nilsson B
Gastroenterology; 2006 May; 130(6):1573-81. PubMed ID: 16697720
[TBL] [Abstract][Full Text] [Related]
3. [Mutation profiles of c-kit/PDGFRα and its associations with clinicopathological characteristics in Chinese gastrointestinal stromal tumors: analysis of 827 cases].
Li Y; Gao J; Tian Y; Li J; Shen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2015 Apr; 18(4):332-7. PubMed ID: 25940173
[TBL] [Abstract][Full Text] [Related]
4. Molecular analysis of the KIT gene in gastrointestinal stromal tumors with novel mutations.
Calibasi G; Baskin Y; Alyuruk H; Cavas L; Oztop I; Sagol O; Atila K; Ellidokuz H; Yilmaz U
Appl Immunohistochem Mol Morphol; 2014 Jan; 22(1):37-45. PubMed ID: 23455185
[TBL] [Abstract][Full Text] [Related]
5. [Analysis of c-kit gene mutations in gastrointestinal stromal tumors].
Hou YY; Sun MH; Tan YS; Wei YK; Lu XY; Zhang TM; Du X; Wang J; Zhu XZ
Zhonghua Zhong Liu Za Zhi; 2004 Feb; 26(2):89-92. PubMed ID: 15059325
[TBL] [Abstract][Full Text] [Related]
6. [c-kit and PDGFRA mutations in 60 cases of gastrointestinal stromal tumors (GISTs)].
He HY; Xiang YN; Li Y; Zhong HH; Wu BQ; Zheng J
Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Jun; 37(3):320-4. PubMed ID: 15968329
[TBL] [Abstract][Full Text] [Related]
7. [Status and clinical implication of c-kit and PDGFRA mutations in 165 cases of gastrointestinal stromal tumor (GIST)].
He HY; Fang WG; Zhong HH; Li Y; Zheng J; Du J; Heng WJ; Wu BQ
Zhonghua Bing Li Xue Za Zhi; 2006 May; 35(5):262-6. PubMed ID: 16776995
[TBL] [Abstract][Full Text] [Related]
8. c-kit gene mutation at exon 17 or 13 is very rare in sporadic gastrointestinal stromal tumors.
Kinoshita K; Isozaki K; Hirota S; Nishida T; Chen H; Nakahara M; Nagasawa Y; Ohashi A; Shinomura Y; Kitamura Y; Matsuzawa Y
J Gastroenterol Hepatol; 2003 Feb; 18(2):147-51. PubMed ID: 12542597
[TBL] [Abstract][Full Text] [Related]
9. The outcome of targeted therapy in advanced gastrointestinal stromal tumors (GIST) with non-exon 11 KIT mutations.
Osuch C; Rutkowski P; Brzuszkiewicz K; Bylina E; Limon J; Siedlecki JA
Pol Przegl Chir; 2014 Jul; 86(7):325-32. PubMed ID: 25222580
[TBL] [Abstract][Full Text] [Related]
10. The analysis of status and clinical implication of KIT and PDGFRA mutations in gastrointestinal stromal tumor (GIST).
Du CY; Shi YQ; Zhou Y; Fu H; Zhao G
J Surg Oncol; 2008 Sep; 98(3):175-8. PubMed ID: 18618605
[TBL] [Abstract][Full Text] [Related]
11. Correlation between mutational status and survival and second cancer risk assessment in patients with gastrointestinal stromal tumors: a population-based study.
Rubió-Casadevall J; Borràs JL; Carmona-García MC; Ameijide A; Gonzalez-Vidal A; Ortiz MR; Bosch R; Riu F; Parada D; Martí E; Miró J; Sirvent JJ; Galceran J; Marcos-Gragera R
World J Surg Oncol; 2015 Feb; 13():47. PubMed ID: 25885906
[TBL] [Abstract][Full Text] [Related]
12. KIT Exon 11 Codons 557-558 Deletion Mutation Promotes Liver Metastasis Through the CXCL12/CXCR4 Axis in Gastrointestinal Stromal Tumors.
Wang HC; Li TY; Chao YJ; Hou YC; Hsueh YS; Hsu KH; Shan YS
Clin Cancer Res; 2016 Jul; 22(14):3477-87. PubMed ID: 26936919
[TBL] [Abstract][Full Text] [Related]
13. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
14. Gastrointestinal stromal tumors with KIT exon 9 mutations: Update on genotype-phenotype correlation and validation of a high-resolution melting assay for mutational testing.
Künstlinger H; Huss S; Merkelbach-Bruse S; Binot E; Kleine MA; Loeser H; Mittler J; Hartmann W; Hohenberger P; Reichardt P; Büttner R; Wardelmann E; Schildhaus HU
Am J Surg Pathol; 2013 Nov; 37(11):1648-59. PubMed ID: 24061512
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group.
Patrikidou A; Domont J; Chabaud S; Ray-Coquard I; Coindre JM; Bui-Nguyen B; Adenis A; Rios M; Bertucci F; Duffaud F; Chevreau C; Cupissol D; Pérol D; Emile JF; Blay JY; Le Cesne A;
Eur J Cancer; 2016 Jan; 52():173-80. PubMed ID: 26687836
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of KIT exon 11 deletion mutation in intermediate-risk gastrointestinal stromal tumor.
Quek R; Farid M; Kanjanapan Y; Lim C; Tan IB; Kesavan S; Lim TKH; Oon LL; Goh BK; Chan WH; Teo M; Chung AY; Ong HS; Wong WK; Tan P; Yip D
Asia Pac J Clin Oncol; 2017 Jun; 13(3):115-124. PubMed ID: 27753268
[TBL] [Abstract][Full Text] [Related]
17. Characterization of GIST/GIPACT tumors by inmunohistochemistry and exon 11 analysis of c-kit by PCR.
Bernet L; Zuñiga A; Cano R
Rev Esp Enferm Dig; 2003 Oct; 95(10):688-91, 683-7. PubMed ID: 14588063
[TBL] [Abstract][Full Text] [Related]
18. Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors.
Rossi S; Sbaraglia M; Dell'Orto MC; Gasparotto D; Cacciatore M; Boscato E; Carraro V; Toffolatti L; Gallina G; Niero M; Pilozzi E; Mandolesi A; Sessa F; Sonzogni A; Mancini C; Mazzoleni G; Romeo S; Maestro R; Dei Tos AP
Oncotarget; 2016 May; 7(21):30109-18. PubMed ID: 27097112
[TBL] [Abstract][Full Text] [Related]
19. Analysis of C-Kit Exon 9, Exon 11 and BRAFV600E Mutations Using Sangers Sequencing in Gastrointestinal Stromal Tumours.
Madhala D; Sundaram S; Chinambedudandapani M; Balasubramanian A
Cureus; 2020 Mar; 12(3):e7369. PubMed ID: 32328381
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic relevance of overexpressions of PKC-θ and DOG-1 and KIT/PDGFRA gene mutations in extragastrointestinal stromal tumors: a Korean six-centers study of 28 cases.
Kim KH; Nelson SD; Kim DH; Choi KU; Kim SJ; Min KW; Jang KS; Paik SS; Oh YH; Chae SW; Sohn JH; Kim HJ; Cho YK; Kim BI; Park DI; Sohn CI; Oh S; Choi SH; Choi YJ; Woo HY; Park YL; Park SJ; Lee SH; Ryu S; DO SI; Kang G; Kim K; Cho YH; Pyo JS
Anticancer Res; 2012 Mar; 32(3):923-37. PubMed ID: 22399613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
